Androgenic Alopecia-Pipeline Review, H2 2016

Androgenic Alopecia-Pipeline Review, H2 2016

  • Products Id :- GMDHC8897IDB
  • |
  • Pages: 70
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Androgenic Alopecia-Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia-Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Androgenic Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 4 and 1 respectively.

Androgenic Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Androgenic Alopecia (Dermatology).

The pipeline guide reviews pipeline therapeutics for Androgenic Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Androgenic Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Androgenic Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Androgenic Alopecia (Dermatology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Androgenic Alopecia (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Androgenic Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Androgenic Alopecia Overview 7

Therapeutics Development 8

Pipeline Products for Androgenic Alopecia-Overview 8

Androgenic Alopecia-Therapeutics under Development by Companies 9

Androgenic Alopecia-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Androgenic Alopecia-Products under Development by Companies 13

Androgenic Alopecia-Companies Involved in Therapeutics Development 14

Aclaris Therapeutics Inc 14

Allergan Plc 15

Almirall SA 16

BiologicsMD Inc 17

Dong-A Socio Holdings Co Ltd 18

Histogen Inc 19

RepliCel Life Sciences Inc 20

RiverTown Therapeutics Inc 21

Samumed LLC 22

Sucampo Pharmaceuticals Inc 23

SWITCH Biotech LLC 24

Androgenic Alopecia-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

(cyclosporine A + minoxidil + RT-175)-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

bimatoprost-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BMD-1341-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

BRM-421-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CB-0301-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

finasteride-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

finasteride-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

HGEN-001-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

RCH-01-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

RK-023-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

setipiprant-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

SM-04554-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule for Androgenic Alopecia-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Androgenic Alopecia-Dormant Projects 58

Androgenic Alopecia-Discontinued Products 59

Androgenic Alopecia-Product Development Milestones 60

Featured News & Press Releases 60

Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles 60

Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01 60

Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan 61

Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial 62

Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial 62

Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia 63

Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient 64

Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research 64

Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 65

Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum 66

May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness 66

Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine 67

Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology 67

Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Figures

Number of Products under Development for Androgenic Alopecia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 27

Number of Products by Stage and Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33

List of Tables

Number of Products under Development for Androgenic Alopecia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Androgenic Alopecia-Pipeline by Aclaris Therapeutics Inc, H2 2016 14

Androgenic Alopecia-Pipeline by Allergan Plc, H2 2016 15

Androgenic Alopecia-Pipeline by Almirall SA, H2 2016 16

Androgenic Alopecia-Pipeline by BiologicsMD Inc, H2 2016 17

Androgenic Alopecia-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 18

Androgenic Alopecia-Pipeline by Histogen Inc, H2 2016 19

Androgenic Alopecia-Pipeline by RepliCel Life Sciences Inc, H2 2016 20

Androgenic Alopecia-Pipeline by RiverTown Therapeutics Inc, H2 2016 21

Androgenic Alopecia-Pipeline by Samumed LLC, H2 2016 22

Androgenic Alopecia-Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 23

Androgenic Alopecia-Pipeline by SWITCH Biotech LLC, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Assessment by Combination Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Androgenic Alopecia-Dormant Projects, H2 2016 58

Androgenic Alopecia-Discontinued Products, H2 2016 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, BiologicsMD Inc, Dong-A Socio Holdings Co Ltd, Histogen Inc, RepliCel Life Sciences Inc, RiverTown Therapeutics Inc, Samumed LLC, Sucampo Pharmaceuticals Inc, SWITCH Biotech LLC

Androgenic Alopecia Therapeutic Products under Development, Key Players in Androgenic Alopecia Therapeutics, Androgenic Alopecia Pipeline Overview, Androgenic Alopecia Pipeline, Androgenic Alopecia Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]